Search for: All records

Several strategies have been developed recently to ensure valid inference after model selection; some of these are easy to compute, while others fare better in terms of inferential power. In this article, we consider a selective inference framework for Gaussian data. We propose a new method for inference through approximate maximum likelihood estimation. Our goal is to: (a) achieve better inferential power with the aid of randomization, (b) bypass expensive MCMC sampling from exact conditional distributions that are hard to evaluate in closed forms. We construct approximate inference, for example, p-values, confidence intervals etc., by solving a fairly simple, convex optimization problem. We illustrate the potential of our method across wide-ranging values of signal-to-noise ratio in simulations. On a cancer gene expression dataset we find that our method improves upon the inferential power of some commonly used strategies for selective inference. 

RNA sequencing data have been abundantly generated in biomedical research for biomarker discovery and other studies. Such data at the exon level are usually heavily tailed and correlated. Conventional statistical tests based on the mean or median difference for differential expression likely suffer from low power when the between-group difference occurs mostly in the upper or lower tail of the distribution of gene expression. We propose a tail-based test to make comparisons between groups in terms of a specific distribution area rather than a single location. The proposed test, which is derived from quantile regression, adjusts for covariates and accounts for within-sample dependence among the exons through a specified correlation structure. Through Monte Carlo simulation studies, we show that the proposed test is generally more powerful and robust in detecting differential expression than commonly used tests based on the mean or a single quantile. An application to TCGA lung adenocarcinoma data demonstrates the promise of the proposed method in terms of biomarker discovery.